Story perspectives

WHO Endorses Weight-Loss Drugs, Redefines Obesity Treatment

9/16/2025

44 4

Summary

Story summary

The World Health Organization (WHO) endorses weight-loss drugs for obesity treatment, indicating a major shift in management strategies.
Draft guidelines suggest GLP-1 receptor agonists for adults with a BMI of 30 or higher, recognizing obesity as a chronic disease.
The guidelines, open for consultation until September 27, aim to redefine obesity, impacting over 1 billion people globally.
WHO highlights the importance of lifestyle changes alongside medication in treating obesity.
The agency is also creating guidelines for children and adolescents, while high treatment costs limit access in low- and middle-income countries.

1 of 1

Story summary

The World Health Organization (WHO) endorses weight-loss drugs for obesity treatment, indicating a major shift in management strategies.
Draft guidelines suggest GLP-1 receptor agonists for adults with a BMI of 30 or higher, recognizing obesity as a chronic disease.
The guidelines, open for consultation until September 27, aim to redefine obesity, impacting over 1 billion people globally.
WHO highlights the importance of lifestyle changes alongside medication in treating obesity.
The agency is also creating guidelines for children and adolescents, while high treatment costs limit access in low- and middle-income countries.